Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CG Oncology (CGON) Gross Margin (2024 - 2025)

CG Oncology filings provide 2 years of Gross Margin readings, the most recent being 32.21% for Q4 2025.

  • On a quarterly basis, Gross Margin fell 13221.0% to 32.21% in Q4 2025 year-over-year; TTM through Dec 2025 was 3.96%, a N/A change, with the full-year FY2025 number at 15.02%, down 11502.0% from a year prior.
  • Gross Margin hit 32.21% in Q4 2025 for CG Oncology, down from 5.34% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 100.0% in Q3 2024 to a low of 32.21% in Q4 2025.